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Extracellular vesicles (EV), comprising microvesicles and exosomes, are particles
released by every cell of an organism, found in all biological fluids, and commonly
involved in cell-to-cell communication through the transfer of cargo materials such as
miRNA, proteins, and immune-related ligands (e.g., FasL and PD-L1). An important
characteristic of EV is that their composition, abundance, and roles are tightly related
to the parental cells. This translates into a higher release of characteristic pro-tumor EV
by cancer cells that leads to harming signals toward healthy microenvironment cells. In
line with this, the key role of tumor-derived EV in cancer progression was demonstrated
in multiple studies and is considered a hot topic in the field of oncology. Given their
characteristics, tumor-derived EV carry important information concerning the state of
tumor cells. This can be used to follow the outset, development, and progression of the
neoplasia and to evaluate the design of appropriate therapeutic strategies. In keeping
with this, the present brief review will focus on B-cell malignancies and how EV can
be used as potential biomarkers to follow disease progression and stage. Furthermore,
we will explore several proposed strategies aimed at using biologically engineered EV
for treatment (e.g., drug delivery mechanisms) as well as for impairing the biogenesis,
release, and internalization of cancer-derived EV, with the final objective to disrupt
tumor–microenvironment communication.
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INTRODUCTION
Extracellular vesicles (EV) are vesicular components released by every cell of an organism. This
broad group consists of small EV or exosomes (sEV; 30–150 nm) characterized by an endocytic
origin, microvesicles (MV; 100 nm–5 µm) shed from the plasma membrane, and apoptotic bodies
(<5 µm) derived from membrane disintegration (1). The study of EV is a process in constant
Abbreviations: ALL, acute lymphocytic leukemia; ALV, artificial lipid vesicles; BTK, Bruton tyrosine kinase; CLL, chronic
lymphocytic leukemia; ctDNA, circulating tumor DNA; CTX, cyclophosphamide; DC, dendritic cell(s); DLBCL, diffuse large
B-cell lymphoma; EBV, Epstein–Barr virus; EGFR, epidermal growth factor receptor; EV, extracellular vesicle(s); HL, Hodgkin
lymphoma; HM, hematological malignancy; HS, heparan sulfate; ICP, immune checkpoint; IFN-γ, interferon-γ; IL6ST,
interleukin 6-signal transducer; MDR, multiple drug resistance; MSC, mesenchymal stem cell(s); MM, multiple myeloma;
MV, microvesicle(s); NK, natural killer(s); NV, nanoparticle(s); PG, proteoglycans; sEV, small extracellular vesicle(s); shRNA,
small hairpin RNA; SIRPα, signal regulatory protein α; SMART, synthetic multivalent antibodies retargeted; TGF-β(1),
transforming growth factor-β(1); TNFR1, tumor necrosis factor receptor 1.
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evolution, where EV characteristics, as well as nomenclature and
isolation, are in continuous improvement (2–5).
Extracellular vesicles can be virtually found in every biofluid,
which makes them relatively easy to recover and analyze (6). In
the early years of EV-focused research, their synthesis and release
were considered as a mechanism to remove harming material
from the cell (7). Nowadays, this notion has been replaced by
considering the mechanism as an active way to transfer material
to targeted cells (1). Indeed the most common and accepted role
of EV is intercellular communication through ligand–receptor
interactions and the transfer of molecular cargoes.
The composition of EV is extremely heterogeneous.
Depending on their nature, origin, physiological context,
and parental cells, EV contain and transfer distinct elements to
targeted cells, such as proteins, nucleic acids, lipids, metabolites,
and organelles (8–10). The interest in understanding the
role of EV in cancer is due to their unique ability to re-
educate and attenuate the normal activity of healthy cells
across the whole body. In line with this, B-cell malignancy-
derived EV have been shown to interact with the surrounding
microenvironment, leading to its profound remodeling. EV-
based communication assists cancer development by stimulating
tumor cell proliferation and migration (11), by modifying distant
microenvironment to generate a pre-metastatic niche (12),
and by strategically inhibiting tumor immune surveillance and
anti-tumor response (13, 14).
EV DIAGNOSTIC AND THERAPEUTIC
POTENTIAL
Due to a complex and parental-cell-dependent molecular cargo
and to their presence in every biological fluid, EV represent
an innovative tool for the design of diagnostic and therapeutic
strategies in B-cell malignancies. In the sections below, we will
explore the multiple potential uses of EV: (i) EV as biomarkers,
(ii) EV as therapeutic targets, (iii) EV in immune evasion and use
in immunotherapy, and (iv) biologically engineered EV (Figure 1
and Table 1).
EV as Biomarkers
Given that EV are continuously released by all the cells and
that they can be recovered from every fluid in the body,
they clearly represent a potential source of biomarkers (15,
16). Compared with most common biomarkers obtained from
liquid biopsies, such as circulating tumor DNA (ctDNA), EV
represent a more reliable source of information and can be
easily incorporated in the diagnostic routine. Specifically, ctDNA
represents only a minimal fraction of plasma-cell-free DNA
(17, 18); thus, despite its high specificity, the starting amount
is already challenging (17, 19). Furthermore, ctDNA is often
affected by high fragmentation and low stability (20, 21). EV
are very stable and, depending on the time of use, can be
stored at different temperatures for extended periods of time
(several weeks at 4◦C, several months at −80◦C, and several
years in liquid nitrogen) (22). Cancer cells generally produce
high amounts of EV that mirror the characteristics—as a sort of
fingerprint—of the parental cancer cells (23–25). Indeed cargo
composition (e.g., microRNA and proteins) and transmembrane
molecules (tumor antigens or immune cell markers) allows the
identification of the parental cell and its physiological state (24,
26). Analysis of EV isolated from patients was confirmed to
be an important tool in the detection of cancer development
at an early stage and to stratify patients based on intrinsic
tumor characteristics and for following patients in remission (16,
27, 28).
In line with this, we have shown that the plasma of a
patient affected by chronic lymphocytic leukemia (CLL) is
highly enriched in multiple key microRNAs (e.g., miR-21,
miR-155, and miR-146a) which can potentially affect multiple
pathways involved in the pathogenesis and the progression of
the disease. MicroRNA expression profile can also be used to
stratify CLL patients in view of a more personalized treatment
and follow-up (29). Importantly, we and others found these
same microRNAs and some additional ones (miR-148a and Let-
7g) also in CLL-derived EV, demonstrating how these vesicles
can indirectly provide information on cellular state (30, 31).
Van Eijndhoven and colleagues detected a higher level of EV
carrying miR-24-3p, miR-127-3p, miR-21-5p, miR155-5p, and
Let7a-5p in the plasma of Hodgkin lymphoma patients compared
with controls. Upon treatment, patients showing remission had
a stable reduction of these miRNAs compared with relapse
patients who displayed their progressive accumulation (32).
Interestingly, a further study performed on a large multiple
myeloma (MM) cohort described that the progression-free
survival and the overall survival of patients could be successfully
followed by monitoring the plasma levels of miR-18a and
Let7b, which were found to be highly enriched in MM-
derived EV (33).
Beyond miRNA content, RNA packed in plasma EV has the
potential to be used to define tumor mutation landscape, such as
BRAF V600E for melanoma, with the aim to detect early-stage
disease or define the best clinical approach for certain patients
(34). This strategy may be transposed to mutated RNA contained
in circulating EV from B-cell malignancies, with the attempt to
perform a personalized patient follow-up and therapy.
EV reflect parental cell also through the presence of cellular
markers on the EV membrane and in their protein cargo (35).
Different studies show that CLL-derived EV from a patient’s
plasma present typical markers of leukemic cells (e.g., CD19,
CD20, CD5, and CD37) and major histocompatibility complex
(e.g., HLA-A, HLA-B, and HLA-C) (36, 37). Despite this
correlation, it is essential to highlight that not all markers or
their possible combinations are always present on EV released
by tumor cells. Indeed CLL cells can release a subset of EV
carrying CD52 but only few CD19 molecules; this particular
marker combination was shown to be characteristic of CLL
patients with advanced disease (38). Another study by Harshman
and colleagues showed the presence of typical MM cell (CD38,
CD138, and CD147) and treatment resistance (CD44)-associated
markers on MM-derived EV isolated from a patient’s serum
(39, 40).
In sum, EV represent a faithful snapshot of the parental
cell that synthesized them. The follow-up of proteins
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FIGURE 1 | Extracellular vesicles (EV) diagnostic and therapeutic potential. (i) EV as biomarkers: multiple physiological characteristics allow EV to be easily collected
from different biological sources (e.g., plasma and urine). Definition of content and carried molecules is essential to determine their origin, thus detecting tumor in
different stages of the disease and in post-treatment follow-ups. (ii) EV as therapeutic targets: biogenesis, release, and uptake are all key steps which can be
targeted in order to decrease the circulating amount and the function of tumor-derived EV. Beyond this, targeting active EV components (e.g., immune checkpoint)
decreases their impact on various aspects on targeted cells. (iii) EV and immunotherapy: tumor cells have the ability to re-educate the immune system via the release
of EV, thus able to affect the function of multiple immune cells. Despite this, tumor-derived EV can be strategically used to build a strong immune response by the
endogenous immune cells (e.g., dendritic cells) and use their EV to diminish cancer cell functions. (iv) Engineered EV: together with nanoparticles, EV can be
modified to carry specific molecules (e.g., shRNA and chemotherapy drugs) and directed to cancer and its microenvironment cells. Engineered EV can be produced
by transformed cell lines (e.g., mesenchymal stem cells) and directed against tumor cells.
and RNAs carried by circulating EV in B-cell malignancy
patients constitutes a promising source of predictive
biomarkers. The low invasiveness of their isolation could
allow regular sampling, and by monitoring EV content,
the evolution of tumors within patients can be followed,
either before or after anti-cancer treatment, allowing
clinicians to select the best course of action for each
specific case.
EV as Therapeutic Targets
Biogenesis, release, and internalization of EV are tightly regulated
processes that involve multiple putatively targetable protein
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TABLE 1 | Overview of the diagnostic and the therapeutic potentials of extracellular vesicles in B-cell malignancies.
EV Role Target B-Cell malignancy References
Biomarker miR-21, miR-155, miR-146a, miR-148a, and Let-7g CLL (29–31)
miR-24-3p, miR-127-3p, miR-21-5p, miR155-5p, and Let7a-5p HL (32)
miR-18a and Let7b MM (33)
CD19, CD20, CD5, CD37, CD52, and MHC CLL (36, 37)
CD38, CD138, CD147, and CD44 MM (39, 40)
Target EV release (indomethacin) DLBCL (42)
EV uptake (low molecular weight heparin) CLL (30)
TGF-β1 (shRNA) ALL (44, 71)
Immune modulator T lymphocytes (DC-derived EV) and DC (poly I:C) ALL (58)
TGF-β1 (shRNA) ALL (44, 71)
Vaccination DC (DLBCL-derived EV) DLBCL (78)
T lymphocytes (DC-derived EV) ALL (64)
Carrier c-Myc (siRNA) Lymphoma (70)
TGF-β1 (shRNA) Lymphoma (44, 71)
CD21 (Gp350) CLL (72)
Apoptosis (Apo2L/TRAIL) MM (73)
CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; MM, multiple myeloma; ALL, lymphocytic leukemia; HL, Hodgkin lymphoma.
complexes. Impairing the pro-tumoral effect of EV can be
achieved by acting through two main axes. On one hand, the
autocrine signals, where EV bind to and modify neoplastic
cells themselves, could be disrupted (41). On the other hand,
the role of EV in the cross-talk between cancer cells and the
supportive microenvironment could be targeted. This can have
a major impact on decreasing tumor survival, proliferation, and
migration (42).
In B-cell malignancies, Koch and colleagues demonstrated
that treating several diffuse large B-cell lymphoma (DLBCL)
cell lines with indomethacin, a non-steroidal anti-inflammatory
drug, suppressed EV release and strongly decreased tumor
progression. They further demonstrated that a decreased EV
release guarantees a more potent effect of cytostatic drugs,
such as anthracyclines and anthracenediones, both in vitro and
in vivo (42). Another strategy implies the reduction of EV
uptake by blocking key factors, e.g., heparan sulfate proteoglycans
(HSPGs), on target cells (41). HSPGs have been suggested to
act as a receptor for EV internalization. In line with this, we
demonstrated that pre-treatment of EV with low molecular
weight heparin, a HS analog, strongly decreases the uptake of
CLL-derived EV by target cells (30).
Several studies have demonstrated how EV have a strong
impact on the immune system, allowing a more efficient tumor
immune evasion (13). One of the characteristics associated
with this phenomenon is the presence of immune checkpoint
(ICP) ligands on tumor-derived EV. Chen et al. (43) recently
showed an increase in PD-L1 molecule on melanoma derived-
EV upon interferon-γ stimulation. Considering that PD-L1 and,
potentially, other ICP molecules are present on EV derived
from B-cell malignancies characterized by a strong immune-
suppressed microenvironment (e.g., CLL), therapies such as
recombinant blocking antibodies can represent an effective
solution in targeting immune-suppressive EV. The same strategy
can also be extended to other EV molecules; for instance,
targeting leukemia-derived EV bearing transforming growth
factor-β1 (TGF-β1) has been shown to improve anti-leukemia
immunity (44).
Molecules carried by tumor-derived EV are not the only
source of harming. EV released by tumor microenvironment
B-cells carry CD39 and CD73, two surface molecules able to
hydrolyze ATP released by dying cancer cells to adenosine and
effectively hijack CD8 T cell immune activity by binding the
A2A adenosine receptors (45). In line with this, it is possible
to speculate that B-cell malignancy-derived EV may have a
similar effect, if not greater, given their higher concentration in
the tumor milieu. The study of Zhang et al. (45) shows that
a decrease of B-cell-derived EV bearing CD73 and CD39 can
be achieved by deregulating the docking protein RAB27A. This
has been performed using an inactivated Epstein–Barr virus-
mediated siRNA, but it is also possible to generate EV (e.g.,
derived from modified stroma cell lines) carrying RAB27A siRNA
and specifically deliver it to tumor cells.
Targeting B-cell malignancy EV represents an interesting
strategy in the treatment of cancer. These approaches imply
obvious risks and limitations, such as possible drug resistance
and off-targets, which can ultimately lead to decreased
efficacy of the therapy.
Role of EV in Immune Evasion and Use in
Immunotherapy
The immune system is one of the main players involved
in cancer cell recognition and elimination (46–48). However,
cancers deploy numerous strategies to repress the immune
system during disease development and, thus, effectively evade
immune surveillance. The concept behind immunotherapy is to
re-activate the patient’s immune system in order to recognize
and remove cancer cells. One example of the many mechanisms
involved in immunoevasion is the use of EV to fully re-educate
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the immune microenvironment, causing a domino effect and
ultimately leading to overall immune repression and cancer
development (13).
Being released by neoplastic cells, EV represent an important
source of selective antigens that educate naïve immune cells (49,
50). As for solid tumors (51–53), leukemia-derived EV are loaded
with antigens and several immunogenic molecules, such as TGF-
β and IL-6, capable to impair dendritic cells (DCs) to build a
specialized immune response against neoplastic cells (54–57).
EV structure and characteristics allow them to specifically drive
DC-dependent immunization; in fact, stimulation of DCs with
only leukemic cell lysate results in failure to build an appropriate
immune response (55, 56).
Immunotherapy can also be used in parallel with
chemotherapy. Guo and colleagues combined leukemia-specific
DC-derived EV with cyclophosphamide and polyinosinic-
polycytidylic acid sodium salt (poly I:C) (58). This combination
is based on the ability of DC-derived EV to stimulate T
lymphocyte proliferation and enhance their cytotoxic activity
against leukemia, while poly I:C acts on DC maturation. This
strategy led to leukemia cell suppression in vitro and increased
survival of tumor-bearing mice (58).
Targeting tumor-derived EV surface molecules is also a
valuable strategy to strongly reduce their activity on immune
cells. As we have previously mentioned, TGF-β1 is enriched
in EV released by a wide range of tumors and, acting on
various immune cells such as DCs, is one of the main causes of
immune escape (57). EV released by acute lymphocytic leukemia
(ALL) L1210 cell line carry high levels of TGF-β1. By using
small hairpin RNA (shRNA), Huang and colleagues knocked
down TGF-β1 in the ALL cell line, thus removing it from
their EV and reconstituting DC maturation and activity in vivo.
Additionally, the same group demonstrated that pulsed DCs were
able to increase T cell proliferation and enhance cytotoxic activity
against ALL cells (44).
Dendritic cells are not the only immune cells that can be
used to re-establish a proper cytotoxic activity against B-cell
malignancies. Another valid target is natural killer (NK) cells,
whose activity is repressed by molecules, such as NKG2D ligands,
exposed on hematological malignancy (HM)-derived EV (59, 60).
One particular study presented a double role of the NKp30 ligand
BAG6 in CLL. First, high levels of soluble BAG6 can be detected
in the plasma of CLL patients, being one of the causes for the
defect in NK cytotoxicity observed in these patients (61). At the
same time, BAG6 is released via EV by healthy cells in response
to cellular stress and has a protective activity by enhancing NK
cytotoxicity (60). Based on this, it is possible to hypothesize that
treatment with BAG6+ EV derived from stressed cells may be a
reliable opportunity to maintain (and possibly to re-establish) NK
activity during cancer development.
Despite their evident activation effects on the immune system,
the use of EV-based vaccination is still under discussion, although
several studies already suggest how EV can be used to build an
effective immune response before tumor cells arise. In line with
this, DC cells pulsed with DLBCL-derived EV have been shown to
stimulate T lymphocyte expansion and, by consequence, increase
anti-lymphoma immunity in mice (62). These results are in
accordance with other studies where leukemia-derived EV can
be used to build anti-leukemia immunity, with evident results
both in vitro and in vivo (54, 63). Finally, Qazi and colleagues
showed that EV antigens alone are enough to induce memory T
lymphocytes through B-cell activation (64).
Altogether these findings position EV as potent immune
modulators that can become a major tool for immunotherapy
and vaccine design.
Engineered EV
The ability of EV to bind to specific receptors on both tumor
and microenvironment cells through surface molecules makes
them an interesting tool to transfer exogenous cytotoxic and
inhibitory molecules for therapeutic purposes (65). Furthermore,
EV represent a useful method to deliver anti-tumor drugs due
to their ability to retain stable concentrations of the components
loaded in them as well as a natural accumulation in vascular sites,
such as inflammation and wounds, tumor, and infection areas
(66–69).
Lunavat and colleagues successfully engineered EV-like
nanoparticles (NV) that contain siRNA and showed that silencing
c-Myc by this approach efficiently activates poly (ADP-ribose)
polymerase-dependent apoptotic pathways in treated λ820
lymphoma cells (70). More recently, shRNA strategy has been
used to silence TGF-β1 in lymphoma cells, forcing them to
release TGF-β1-depleted EV. By removing this strong antitumor–
immune surveillance inhibitor, the authors achieved an increase
in the response of the immune system against leukemic cells
(71). In line with this, engineered EV were also used to
transfer specific antigens, with the purpose of re-activating or
enhancing the immune system. Stromal cells transfected with
the Epstein–Barr virus (EBV) protein gp350 release gp350+ EV
that specifically interacts with CD21 on B-cells. Gp350+ EV were
further engineered to carry CD154. By treating CLL patients’
cells, the authors achieved the internalization of EV in leukemic
cells and a strong immunogenic effect, leading to a dual activation
of tumor-associated and EBV-specific T cells (72).
Further strategies based on EV-like nanostructures have been
explored in B-cell malignancies. Artificial lipid vesicles (ALV)
decorated with bioactive Apo2 ligand/TNF-related apoptosis-
inducing ligand were tested on lymphoma and MM cell lines.
These novel ALV showed a consistent pro-apoptotic effect in
multiple HM cell lines while sparing normal cells (such as
CD4+ and CD8+ T cells) in vitro and with no sign of toxicity
in vivo (73).
Engineered EV can be broadly produced in vitro using a
wide range of cell lines. Mesenchymal stem cells (MSCs) have
been shown to be a valuable tool for the production of EV with
high tropism toward tumor cells. In line with this, MSCs can
be modified to release engineered EV with various downstream
applications and means (74).
As mentioned before, ICPs on EV surface are important
targets for immunotherapy. As alternative to monoclonal
antibodies, EV released by modified MSCs can be used as
antagonists for delivering immune checkpoint blockade proteins
(e.g., ICP receptors or monoclonal antibodies) (75). A further
well-known immune escape strategy applied by tumors is the
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overexpression of CD47, also carried by tumor-derived EV,
which interacts with the signal regulatory protein α (SIRPα) on
phagocytic cells, limiting their activity (76). The production of
EV bearing SIRPα molecules has been shown to successfully
hamper the tumor “don’t-eat-me” signal in favor to macrophage
phagocytosis (77).
Recently, a new class of engineered EV has been tested,
with the aim to enhance T cell activity against tumor cells.
Synthetic multivalent antibodies retargeted (SMART) EV bear
monoclonal antibodies against CD3 and cancer cell-associated
epidermal growth factor receptor (EGFR). These characteristics
allow them to act as a bridge directing T cytotoxic cells toward
tumor cells, thus inducing crosstalk and enhancing antitumor
response (78). SMART EV may have a potential application on
MM due to its high level of EGFR, which guarantee proliferation
and resistance to conventional therapies (79, 80). Furthermore,
the same strategy could be applied for other B-cell malignancies,
such as CLL and lymphoma, by targeting highly enriched
surface molecules.
EV are also able to epigenetically reprogram target cells
and to completely change their phenotype in a short time (81,
82). A potential strategy in the re-activation of the immune
system can be to inhibit the molecules responsible for this deep
change as well as creating engineered EV carrying specific cargo
components (e.g., siRNA and shRNA) that are able to lift the
immune cell exhaustion by rewiring the epigenetic landscape.
An interesting application for engineered EV is to use
them as an instrument for decoy of cytokines (e.g., pro-
inflammatory cytokines). This strategy actively restrains tumor
effect on microenvironment cells (e.g., reducing inflammation).
An example comes from a recent preprint where stroma-derived
EV were engineered to bear tumor necrosis factor receptor
1 and interleukin 6-signal transducer. The authors reported
striking effects concerning inflammation reduction and survival
of experimental mouse models (83). A possible application of
this strategy in B-cell malignancies would be to decoy important
cytokines related to immune suppression, such as IL-10 and
TGF-β1 (44, 84).
Various studies have successfully used EV as a drug delivery
system. The rationale to generate EV containing specific drugs
is based on cell ability to encapsulate exogenous material and
release either actively (e.g., microvesicles budding) or by cellular
death consequence (apoptotic bodies). Based on this, EV released
by drug-treated tumor cells have been used to deliver specific
chemotherapeutic agents to untreated tumor cells (85). EV-
based drug delivery has been tested on various cancer models,
including multiple drug resistance (MDR). In each case, EV
shielded the therapeutic agents and delivered them to tumor
cells, demonstrating a higher cytotoxic effect compared with its
administration alone (85, 86). Furthermore, Osterman et al. (87)
have shown how EV can be used to encapsulate toxic drugs, such
as curcumin, and be specifically directed to cancer cells, highly
reducing any side effect. Despite the fact that no EV-based drug
delivery has been established for B-cell malignancies, strategies
to encapsulate chemotherapeutic agents should be explored. One
of the many possibilities could be to encapsulate the ceramide
supplement C6 in EV to target MM cells. Indeed Chang and
colleagues showed in vitro how C6 ceramide treatment leads
to increased apoptosis and block the proliferation of MM
cells by upregulating miRNA clusters such as miR-202 and
miR-16 (88).
Engineered EV, as well as artificial NV, are powerful and plastic
tools to be deployed against B-cell malignancies. As mentioned
above, it is evident that one of the multiple advantages lies in the
possibility to combine this strategy with other well-established
approaches, such as those aiming at reactivating the host immune
system. Furthermore, using engineered EV with a tropism toward
specific cells may improve the targeting of tumor EV. Loading
shRNA into these delivery systems has the potential to reduce
tumor EV production, release, and uptake. Finally, it is important
to consider the high affinity of engineered EV for tumor cells as
a strategic tool to deliver chemotherapy drugs, thus reducing any
off-target side effects.
ONGOING CLINICAL TRIAL USING EV
Several clinical trials involving EV are currently ongoing. In
cancer, the vast majority are applied to solid tumors. The
aims are various: to establish novel sources and standardized
methods to isolate EV from patients (NCT03821909), to
deepen the characterization of cancer EV as predictive
biomarkers (NCT03830619), to develop EV-based vaccination
(NCT01159288), and finally to further improve EV-based
treatment (NCT03608631).
In reference to B-cell malignancies, the ExoReBly project
(NCT03985696) has the overall aim to characterize DLBCL-
derived EV from patients’ samples. The rationale of this clinical
trial is based on the fact that half of the patients subjected to
immunotherapy—typically with the aim to stimulate immune
activity against CD20—fails to show any benefit. The major
hypothesis is that the presence of a high amount of CD20 and
PD-L1, present on DLBCL-derived EV, acts as a decoy target for
rituximab antibody and as a strong immunosuppressive signal,
respectively, leading to therapeutic resistance. Apart from the
characterization of DLBCL-derived EV, the project aims to use
these EV as a marker of response to therapy and disease outcome.
Interestingly, we made a similar observation with CLL-derived
EV presenting high levels of CD20 on their surface and being
able to act as a decoy for rituximab, potentially highlighting a
conserved mechanism among B-cell malignancies (30).
With over 70 clinical trials, EV are gaining more attention in
view of practical and clinical applications. A small percentage of
these clinical trials take in consideration HM, and only one is
being developed in B-cell malignancies. Nevertheless, every year,
new information concerning EV impact on cancer progression
is generated, which strongly suggests that more applications
for HM will arise.
CONCLUSION
The path to decipher the complex characteristics of EV
composition in B-cell malignancies, as well as the biological
role that they accomplish in the behavior of tumors, has shown
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important advances in the last decade. The increasing amount of
novel data recently generated reflects a continuous interest for
studying EV within the community, due in part to their potential
as a tool to improve cancer diagnosis and therapy. It is now well
established that EV can mirror the tumor cells they originate
from and can carry key targetable molecules strongly related to
cancer biology, like immune checkpoints among many others.
Consequently, several additional important discoveries herein
summarized pinpoint a central role attributed to EV in B-cell
driven diseases diagnosis and follow-up and for putative novel
treatment strategies.
However, these reports remain in the area of translational
research but are not yet successfully translated to clinical
applications for patients with B-cell malignancies. While the
treatment of solid cancers using an EV-derived rationale is
already ongoing in advanced clinical trial phases, this is neither
the case for the diagnosis and the follow-up nor for any treatment
in B-cell-originated neoplastic diseases. The fact that EV-based
approaches work properly in other chronic neoplastic and non-
neoplastic diseases represents a motivation to fully enhance
initiatives that use this rationale in HM in the near future. Thus,
the upcoming decade will hopefully shed light into the clinical
applicability of EV as a powerful tool for patients with B-cell
neoplastic disorders.
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